One of Asia's Most Important Events with over 4,500 Attendees
Nuvilex, Inc. (OTCQB:NVLX) announced its affiliate was invited to present at the recent BIO KOREA 2011 conference and exhibition held in Seoul, Korea. BIO KOREA is one of Asia's most important biotech events that included internationally renowned speakers and major pharmaceutical companies. The event covered a diverse range of applications and areas, including clinical drug development, medical devices, tissue engineering, stem cells, therapeutics, biotechnology patenting and licensing, and diagnostics and personalized medicine.
Dr. Eva Maria Brandtner, chief scientist at SG Austria, presented the proprietary cell encapsulation technology Cell-in-a-Box®, which can be associated with all of the key areas covered in this meeting. Around 4,500 people from all over the world attended the meeting, including the biotechnology industry, research institutes and academic organizations.
Stem cell therapy is a major interest of the Korean biotech industry. Nuvilex President and CEO, Dr. Robert F. Ryan, said, "We are pleased there was great interest in the Cell-in-a-Box® technology and its potential applications for many of the attendee's areas of expertise. In addition, since this was attended by major global pharmaceutical and biotechnology leaders, there was keen interest in other uses of the live cell encapsulation technology. It is gratifying that presenting at yet another key biotech event has increased awareness of the unique advantages and applications of the proprietary cell encapsulation technology."
About Nuvilex
Nuvilex, Inc. (OTCQB: NVLX) is an innovative biotechnology and natural products company whose oncology offerings include cancer treatment using the company's industry-leading live-cell encapsulation technology. Current biotechnology-based products include Cell-in-a-Box® and Bac-in-a-Box® live cell encapsulation products and natural products include Cinnergen™, including the 3 oz. travel size Cinnergen™, Cinnechol™, flu treatment, tattoo inks, antimicrobial and antinematodal agents.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Contacts:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
mmolinarofc@aol.com
